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Consolidated criteria for reporting qualitative 
research (COREQ): a 32-item checklist for 
interviews and focus groups 
Table 1  
Consolidated criteria for reporting qualitative studies (COREQ): 32-item checklist 
No Item Guide questions/description  
Domain 1: 
Research team 
and reflexivity 
  
 
Personal 
Characteristics   
 
1. 
Inte viewer 
/facilitator 
Which author/s conducted 
the interview or focus group? 
RJS, KK, ME, AH, MS, EM 
2. Credentials 
What were the researcher's 
credentials? E.g. PhD, MD 
RJS, KK, ME, AH, MS highest 
qualifications are PhD,  
EM highest qualification is 
MSc 
3. Occupation 
What was their occupation at 
the time of the study? 
RJS, KK, ME, MS, EM are 
research fellows 
AH is a rheumatologist  
 
4. Gender 
Was the researcher male or 
female? 
Mixture of male and female 
5. 
Experience and 
training 
What experience or training 
did the researcher have? 
All have extensive experience 
and training  
Relationship 
with 
participants 
  
 
6. 
Relationship 
established 
Was a relationship 
established prior to study 
commencement? 
Invitation letters were sent, 
participants were spoken to 
over the phone and before 
the interview commenced 
participants were given an 
overview of the research 
study.  
7. 
Participant 
knowledge of 
the interviewer 
What did the participants 
know about the researcher? 
e.g. personal goals, reasons 
for doing the research 
Participants were given 
participant information 
sheets, and given a verbal 
introduction to the study, its 
aims and the procedure. 
8. 
Interviewer 
characteristics 
What characteristics were 
reported about the 
interviewer/facilitator? e.g. 
Bias, assumptions, reasons 
The interviewers were from a 
range of backgrounds 
including medicine, 
psychology and social 
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No Item Guide questions/description  
and interests in the research 
topic 
sciences.  
Domain 2: 
study design   
 
Theoretical 
framework   
 
9. 
Methodological 
orientation and 
Theory 
What methodological 
orientation was stated to 
underpin the study? e.g. 
grounded theory, discourse 
analysis, ethnography, 
phenomenology, content 
analysis 
 Yes, thematic analysis  
Participant 
selection   
 
10. Sampling 
How were participants 
selected? e.g. purposive, 
convenience, consecutive, 
snowball 
Convenience  
11. 
Method of 
approach 
How were participants 
approached? e.g. face-to-
face, telephone, mail, email 
Mail 
12. Sample size 
How many participants were 
in the study? 
34 
13. 
Non-
participation 
How many people refused to 
participate or dropped out? 
Reasons? 
None participation rates 
across the centres were 
problematic to calculate 
accurately.  
Main reasons for not 
participating were difficulties 
in arranging suitable times 
and locations for interviews. 
Setting 
  
 
14. 
Setting of data 
collection 
Where was the data 
collected? e.g. home, clinic, 
workplace 
Clinical and academic 
settings.  
15. 
Presence of 
non-
participants 
Was anyone else present 
besides the participants and 
researchers? 
Interviews were conducted 
on a one-to-one basis.  
16. 
Description of 
sample 
What are the important 
characteristics of the sample? 
e.g. demographic data, date 
The characteristics of the 
sample are presented in the 
tables contained within the 
paper  
Data collection 
  
 
17. Interview guide Were questions, prompts, Yes, the interviews were 
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No Item Guide questions/description  
guides provided by the 
authors? Was it pilot tested? 
semi-structured  
18. 
Repeat 
interviews 
Were repeat interviews 
carried out? If yes, how 
many? 
No 
19. 
Audio/visual 
recording 
Did the research use audio or 
visual recording to collect the 
data? 
Digital audio recorders were 
used.  
20. Field notes 
Were field notes made during 
and/or after the interview or 
focus group? 
No 
21. Duration 
What was the duration of the 
interviews or focus group? 
60-90 minutes  
22. Data saturation 
Was data saturation 
discussed? 
Yes, thematic saturations was 
achieved.  
23. 
Transcripts 
returned 
Were transcripts returned to 
participants for comment 
and/or correction? 
An interactive feedback 
process was used were 
transcripts were reflected 
and commented upon, 
however, transcripts were 
not feedback to participants 
for correct.  
Domain 3: 
analysis and 
findingsz  
  
 
Data analysis 
  
 
24. 
Number of 
data coders 
How many data coders coded 
the data? 
Five  
25. 
Description of 
the coding tree 
Did authors provide a 
description of the coding 
tree? 
No, instead major themes 
were identified.  
26. 
Derivation of 
themes 
Were themes identified in 
advance or derived from the 
data? 
Themes were derived from 
the data 
27. Software 
What software, if applicable, 
was used to manage the 
data? 
NVIVO 
28. 
Participant 
checking 
Did participants provide 
feedback on the findings? 
No 
Reporting 
  
 
29. 
Quotations 
presented 
Were participant quotations 
presented to illustrate the 
themes / findings? Was each 
quotation identified? e.g. 
Yes, see tables 2, 3 and 4.  
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No Item Guide questions/description  
participant number 
30. 
Data and 
findings 
consistent 
Was there consistency 
between the data presented 
and the findings? 
Yes 
31. 
Clarity of major 
themes 
Were major themes clearly 
presented in the findings? 
Yes, major themes were 
identified.  
32. 
Clarity of minor 
themes 
Is there a description of 
diverse cases or discussion of 
minor themes? 
Yes 
 
Page 4 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
1 
 
Title: Perceptions of risk and predictive testing held by the first degree relatives of 
patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study  
 
Authors 
Rebecca J Stack
1,2
,  Michaela Stoffer
3,4
, Mathias Englbrecht
5
, Erika Mosor,
3
 Marie Falahee
1
,  
Gwenda Simons
1
,  Josef Smolen
3
, Georg Schett
5
, Chris D Buckley
1,2
,  Kanta Kumar
6
,  Mats 
Hansson
7
, Axel Hueber
5
, Tanja Stamm
3
, Karim Raza
1,8
 
 
Affiliations 
1. Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University 
of Birmingham, UK 
2. Division of Psychology, Nottingham Trent University, Nottingham, UK 
3. Division of Rheumatology, Department of  Internal Medicine III Medical University of 
Vienna, Austria 
4. University of Applied Sciences for Health Professionals, Upper Austria, Austria 
5. Department of Internal Medicine 3, University of Erlangen-Nuremberg,  Erlangen, 
Germany 
6. School of Nursing, Faculty of Medical and Human Sciences, University of Manchester, UK 
7. Centre for Research Ethics and Bioethics, Uppsala University, Sweden 
8. Department of Rheumatology, Sandwell & West Birmingham Hospitals NHS Trust, 
Birmingham, UK 
 
Correspondence to: 
Dr. Rebecca J Stack, Division of Psychology, School of Social Sciences, Nottingham Trent 
University, NG14BU, UK rebecca.stack@ntu.ac.uk  
 
Keywords 
Risk, Rheumatoid Arthritis, First-degree Relatives, Predictive testing, Qualitative 
 
  
Page 5 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
2 
 
Abstract 
 
Objectives: The family members of rheumatoid arthritis (RA) patients are at increased risk 
of developing RA and are potential candidates for predictive testing. This study explored the 
perceptions of first degree relatives of people with RA about being at risk of RA and 
engaging in predictive testing.   
 
Methods: Thirty-four first-degree relatives (siblings and off-spring) of patients with RA from 
the UK, Germany and Austria participated in semi-structured interviews about their 
perceptions of RA isk and the prospect of predictive testing. Interviews were audio-
recorded, transcribed verbatim and analysed using thematic analysis.  
 
Results: First-degree relatives were aware of their susceptibility to RA, but were unsure of 
the extent of their risk. When considering their future risk, some relatives were concerned 
about the potential impact that RA would have on their lives. Relatives were concerned that 
knowing their actual risk would increase their anxiety and would impact decisions about 
their future. Also, relatives were concerned about the levels of uncertainty associated with 
predictive testing. Those in favour of knowing their future risk felt that they would need 
additional support to understand the risk information and cope with the emotional impact 
of this information.  
 
Conclusions: Identifying individuals at risk of RA may allow targeted interventions to reduce 
the risk and consequence of future disease; however, relatives have concerns about 
predictive testing and risk information.  The development of strategies to quantify and 
communicate risk needs to take these views into account and incorporate approaches to 
mitigate concerns and minimize the psychological impact of risk information. 
 
Strengths and limitations  
• This study used inductive qualitative interviews to explore perceptions about risk 
and predictive testing in the first-degree relatives of people with RA.  
• This study identified positive and negative perspectives surrounding predictive 
testing, and why some people at risk may not wish to be tested.    
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• Further research is needed to quantify the numbers of people at risk holding 
negative perceptions about predictive testing, and identify the behavioural 
implications of these beliefs.  
• Communicating risk information to relatives effectively while reducing the 
psychological burden associated with this information, should be the focus of future 
interventional research. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic destructive polyarthritis. It affects approximately 1% 
of the population 
1
 and  typically manifests in the 4
th
 and 5
th
 decades of life.
2-4
  Delays in 
diagnosis and treatment of RA are common and are associated with worse outcomes.
5-8
 
Recently, an increased research effort has been directed towards the ‘at risk’ phases of RA, 
prior to the development of clinical signs of joint swelling, to identify those at risk of 
developing RA and to reduce this risk through the modification of environmental risk factors 
and pharmacological intervention.
9;9-11
 
Genetic factors contribute significantly to the risk of RA.
12
 For seropositive RA at least half of 
the risk is conferred by genetic risk factors 
13
 with recent large genetic studies having 
identified over 100 susceptibility loci.
14;15
 Population based epidemiological studies have 
shown that having a family history of RA increases the risk of RA by approximately 3-5 
times,
16-18
 with the risk being higher in first degree relatives than second degree relatives.
17
 
Furthermore, a range of environmental and life-style risk factors including occupational 
exposure to pollutants,
19
 body mass index,
20
  periodontitis,
21
  reproductive factors,
22
 
smoking,
23
 and dietary factors
24-26
 contribute to the increased risk of developing RA. Some 
of these environmental risk factors may interact mechanistically with genetic risk factors to 
increase the risk of RA,
27
 and others may have familial associations thus contributing to the 
familial aggregation of RA.
28;29
  
 
Individuals with genetic and environmental risk factors for RA may progress through a phase 
associated with the development of systemic autoimmunity (e.g. the development of 
autoantibodies such as rheumatoid factor,
30;31
 anti–citrullinated protein / peptide 
antibodies and anti-carbamylated protein antibodies
32
) before the clinical symptoms and 
signs of RA manifest.
9
 It remains unclear whether there are changes detectable within the 
synovium during the phase of autoantibody positivity prior to the development of joint 
swelling.
33;34
  
 
Together these data suggest that information related to genotype, environmental exposures 
and measures of autoimmunity and inflammation may be used to predict RA development 
in individuals who have not yet developed clinical disease. A potential target population for 
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such testing, with a view to risk stratification and intervention to modulate risk, are the first-
degree relatives of individuals with RA. Indeed a number of ongoing prospective studies are 
recruiting the first-degree relatives of patients with RA to study disease mechanisms driving 
the switch to RA,
35
 to develop predictive algorithms for RA, and to test interventions to 
reduce RA risk.
36
 Whilst considerable research effort is thus focussed on the first-degree 
relatives of RA patients, and a qualitative study has gathered data relating to their views of 
preventive strategies,
37
 little is known about how such individuals view issues related to 
their susceptibility to and risk of developing RA, and  how willing they would be to be 
assessed and tested to have this risk quantified. The present qualitative study addresses 
these issues.  
 
Methods 
Ethical approval was obtained in the UK from the HumberBridge National Research Ethics 
Committee, in Austria from the Ethics Committee of the Medical University of Vienna and in 
Germany from the Ethics committee of the University of Erlangen-Nuremberg.  
  
 
Procedure  
 
Eligible participants were the first-degree relatives (offspring and siblings) of people with 
RA. Participants were required to be at least 18 years of age and without a diagnosis of 
inflammatory joint disease.   
 
Patients with RA were approached during routine secondary care clinics in Birmingham 
(United Kingdom), Erlangen (Germany) and Vienna (Austria) and were given a letter to pass 
on to a first-degree relative of their choosing inviting them to participate in an interview 
about risk and predictive testing for RA. Participants were recruited between October 2014 
and October 2015. It was explained to patients that it was entirely at their discretion 
whether to pass on the invitation letter. All research participants (i.e. the participating first-
degree relatives) gave written informed consent prior to interview. 
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The semi-structured interviews were guided by an interview schedule which was informed 
by a review of the qualitative literature exploring perceptions of risk and testing in those at 
risk of developing a chronic disease.
38;39
 The interviews aimed to assess personal 
perceptions of risk, therefore, one-to-one interviews were conducted. In addition, an 
international multi-disciplinary team of healthcare professionals, patient research partners 
and researchers working on the EuroTEAM project (www.team-arthritis.eu) reviewed and 
redrafted the interview schedule (see table 1 for sample questions from the final interview 
schedule).  
 
One-to-one Interviews were conducted at local hospitals or by telephone (for those 
participants who had difficulty in attending the hospital for a face-to-face interview). 
Interviews lasted between 30 and 90 minutes and were digitally audio-recorded. In the UK, 
participants who wanted further information about arthritis were advised to contact 
Arthritis Research UK, the National Rheumatoid Arthritis Society or the local hospital’s 
Patient Advice and Liaison Service. Participants in Austria and Germany were advised to 
contact the local rheumatology outpatient clinic.  
 
The interviews were transcribed verbatim. Interviews conducted in German were translated 
into English following transcription. Transcripts were anonymised and analysed centrally in 
Birmingham, UK, by RJS.  
 
Analysis procedure 
Data collection and analysis were carried out in parallel to assess when thematic saturation 
of major developing themes had been achieved. The data were analysed using a thematic 
approach
40
 facilitated by NVivo (a qualitative software programme).
41
 Transcripts were 
subjected to line-by-line coding by RJS. Patient research partners blind coded three 
transcripts to develop reliable and inclusive themes informed by multiple perspectives. 
Discussion of the coding framework took place between researchers and patient research 
partners. Coding categories that lacked concordance were discussed and absorbed into the 
coding framework. The initial codes were then grouped into the most noteworthy and 
frequently occurring categories. The core themes extracted and presented here focus on 
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perceptions of first-degree relatives about their personal risk of RA and their views on being 
tested.   
 
Results  
 
Thirty-four first-degree relatives of patients with RA participated, 24 from the UK, 3 from 
Germany and 7 from Austria.  Six participants were siblings of an RA patient, 26 were the 
adult offspring an RA patient and 2 participants had both a sibling and a parent with RA. 
Participants were aged between 23 and 67 years (mean 39 years) and 26 (76%) were female 
(see table 2 for participant characteristics).  Quotations are presented in tables 3, 4, 5 and 6 
and are referred to in the text using “Q” followed by the quotation code.  
 
Understanding of family history and genetic factors as risk factors for RA  
The first-degree relatives of people with RA understood that there was a hereditary 
component to RA (Q1), and often used the word “genetic” to describe the cause of their 
increased risk (Q2).  First-degree relatives (from here on referred to as “relatives”) 
recognised that they were more susceptible to developing RA than second-degree relatives 
(Q3). Interestingly, some felt that they were more susceptible to developing RA than other 
first-degree relatives because they appeared to follow other patterns of illness displayed by 
their relative with RA (Q4).  Additional biological factors, such as being female and some 
environmental factors were also described as playing a role in the development of RA 
(Q2&5).   
 
When considering their perceived personal susceptibility, relatives reported that there were 
aspects of familial risk, particularly genetic susceptibility, which they found difficult to 
understand. One relative felt that effectively communicating an understanding of genetic 
risk to the public was extremely challenging (Q6). Others felt that they needed more 
information about their level of risk as a relative and the specific role that genes associated 
with RA played in this risk (Q7).  
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When considering their susceptibility to RA, relatives voiced their concerns about the future, 
and how being at risk of developing RA was a worry for them. Those who had considered 
their personal susceptibility to RA, described being fearful of what they may uncover if they 
were to have their risk quantified. For some, the prospect of living with RA would entail 
great amounts of uncertainty (Q8). For many, having witnessed the impact of RA on their 
sibling / parent, heightened the worry they felt in relation to the possibility of developing RA 
themselves in the future (Q9). Interestingly, a small number of relatives had experienced 
joint related symptoms but had not yet sought medical advice, being fearful of the potential 
outcome (Q10).  
 
Personal considerations of RA risk and communication about risk within families  
Relatives discussed knowing little about RA or its risk factors, feeling that they had been 
“shielded” or “protected” from this knowledge by their sibling / parent (Q11). Also, relatives 
described how they rarely discussed RA within their family unit, and in some cases the 
invitation to participate in this study was the first time that the opportunity to discuss RA, 
and its risk had emerged (Q12). For one relative, receiving the invitation to take part in this 
study facilitated the first conversation he had had with his father about RA (Q13). Another 
described how his mother had had some concerns about him taking part in this study, 
because of the worry which discussing issues surrounding risk and predictive testing may 
cause (Q14). One relative described how her brother had been asked to take part in this 
study, but ignored the request; her mother had then approached her and encouraged her to 
participate (Q15). This relative suggested that it was her attitude towards health which set 
her apart from her brother.   
Most relatives had not fully considered issues related to their personal susceptibility to RA 
prior to being approached to take part in this study (Q16).  Some relatives indicated that 
taking part in this study had been a positive experience for them and had provided them 
with much needed knowledge, a chance for reflection on their risk and a greater 
understanding of RA and how it affected their sibling / parent (Q17). However, others 
described how they would prefer to avoid considering their personal risk of RA to avoid 
experiencing worry or anxiety about the future (Q18). 
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Perceptions surrounding the use of predictive tests: positive perspectives 
Most relatives were in favour of the basic principle behind predictive testing - identifying 
those at risk and quantifying the level of risk (Q19). It was also felt that the information 
gained from predictive testing could be acted upon to reduce the future risk of developing 
RA (Q20). In particular, relatives recognised the importance of early intervention, and were 
aware that testing could put them “on alert” for the early symptoms of RA (Q21), or 
suggested that they might be able to take preventive treatment (Q22). Many relatives felt 
that it was important to know that they were at risk, and that information related to their 
actual risk would be of value to them, allowing them to “mentally” prepare for the future 
(Q23). Others could see the benefit of preparing for the functional limitations that may be 
associated with RA (Q24).  A few had already undertaken predictive testing to explore their 
personal risk of developing RA (Q25). Some were willing to be tested for altruistic reasons 
such as taking part in research (Q26).   
 
Perceptions surrounding the use of predictive tests: negative perspectives 
The ability of predictive tests to quantify risk was widely discussed (Q27), with one 
participant questioning the specificity and sensitivity of the test (Q28). Relatives expressed a 
desire for tests that would, with a very high likelihood, be able to confirm or exclude the fact 
that they would develop RA (Q29). However, many relatives suspected that test results 
would give them an intermediate risk of developing RA and others highlighted concerns 
about “false positive” results (Q30). Some believed that predictive testing would not be able 
to give them answers to questions they thought were important for example how severe 
would their RA be   were they to develop it,  and when it would be most likely to begin 
(Q31). 
Relatives were worried about the impact of testing on their family members and in 
particular on their sibling / parent with RA (Q32). Participants felt that by seeking 
information about risk and pursuing testing that they would cause their relative with RA to 
experience stress, worry or feelings of guilt. Participants were further worried about the 
stress that predictive test results may cause them. One even suggested that such stress 
could cause the disease to develop earlier than it otherwise would (Q33).  
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Relatives felt that being given risk information when they were young would be a particular 
burden (Q34). Instead, they felt that testing should be left until later in life, when the 
chance of developing a condition like RA was higher. Risk information was considered to 
have significant implications for future life choices and could make them “rush” though life 
(Q35). One relative suggested such information could bring forward major life decisions, such 
as having children (Q36).   
 
Some relatives reflected upon previous negative personal experiences of having received 
poorly communicated test related information (Q37). For some, the approach to the 
delivery of risk information represented an important feature of a predictive test, and may 
determine whether the test would be acceptable to them. Relatives discussed how they 
would want to be told prior to the test what format the result would take. Some suggested 
that they would like to receive the results by letter, and then be given the opportunity to 
discuss the results with a healthcare professional (Q38). Other relatives emphasized the 
importance of talking to someone about the test result, especially to manage the 
psychological distress that may be associated with receiving a “positive” test result (Q39).  
Many relatives felt that there was a need for ongoing support from a healthcare 
professional following testing (Q40).  
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Discussion 
This study explored the degree to which first-degree relatives of people with RA felt that 
they were susceptible to developing RA and their perceptions of predictive testing. Most 
relatives were aware that there was a genetic contribution to the risk of RA, and that they 
may be susceptible to developing RA; however they were unsure of the extent of the 
additional risk. Relatives highlighted the need for additional information about familial risk 
and described the need for better communication strategies in relation to imparting this 
information.  
 
Generally, first-degree relatives felt that there was a need for more information and support 
specifically designed for the family members of people with RA. The current lack of support 
and information was suggested to have a number of effects, including family members not 
feeling able to communicate and support the person affected with RA and not feeling able 
to understand concepts surrounding the nature of RA and the risks associated with RA. 
Studies of information sharing amongst family members at risk of cancer have found that 
patients with the disease do not always communicate risk information in a timely or 
thorough fashion.
42
 Forrest et al found that relatives from smaller families, and female 
relatives were more likely to make contact with genetic services.
43
 Research has shown that 
genetic counselling can facilitate interfamily communication, and can help to minimize 
distress and increase the number of family members making c ntract with health services to 
be tested.
44;45
 
 
An incidental finding of this research was that being invited to take part in research about 
risk was the first time that some relatives had fully considered their personal susceptibility 
to RA. In some cases this exposure was viewed positively but in other cases it caused worry 
and concern. It is difficult to draw conclusions about the specific impact taking part in this 
study had on relatives’ well-being but we note that relatives did indicate that support 
mechanisms would be helpful to enable them to understand and cope with risk related 
information, especially if predictive testing were to be offered. We would suggest that 
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researchers accessing participants in “at risk” populations pay particular attention to the 
impact that an invitation to participate and participation itself may have, and offer 
additional support to mitigate against anxiety caused. While personal susceptibility may not 
have been considered, perceptions of RA severity may predict personal willingness to 
engage in predictive testing. It is possible that first degree relatives of people with more 
severe forms of RA or poorly controlled disease maybe more motivated to engage in 
predictive testing. This would be in line with the predictions of the health belief model.
46
 A 
quantitative investigation to assess the effect of factors such as disease severity in people 
with RA, on their family members’ perceptions of risk and orientation towards predictive 
testing is needed to test this hypothesis.  
 
In addition, it became apparent during the course of this study that some relatives were 
symptomatic but had not yet sought medical help. Detailed information on the health status 
of the participating relatives was not gathered within this study but those who were 
symptomatic were advised to speak to their family physician, and were given details of 
resources for obtaining additional information. However, the symptomatic nature of some 
relatives raises important issues surrounding informing relatives about risk, and the 
importance of seeking help quickly should symptoms emerge. While some relatives were 
aware that their symptoms may be indicative of the early stages of RA, and were worried 
about what information would be revealed to them if they sought help, few were aware of 
the importance of early intervention. Were information about the benefits of early 
intervention in preventing joint destruction made available to them, it is possible that their 
attitude to help seeking may have been different. 
 
This study has a number of limitations. Firstly, our access to first-degree relatives was via 
patients with RA. Some relatives described how they were chosen in preference to other 
relatives, who would either worry too much or not be receptive to discussing issues related 
to risk. The findings presented here may thus not fully reflect the range of views related to 
risk and testing held by first-degree relatives. This potential limitation highlights the need to 
fully understand the barriers that patients with RA face when discussing issues of risk with 
family members. A second limitation of this research was that the majority of participants 
were female. A criticism of many qualitative studies in the field of RA is that the male 
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perspective is underrepresented.
8
 While the female: male ratio of RA is typically 2:1 it is 
essential that studies attempt to include the views of more male participants. Therefore, we 
acknowledge that themes related to gender and male perspectives of risk and predictive 
testing did not reach saturation and are not represented in our data. A final limitation is that 
only a small number of individuals from ethnic-minority communities were interviewed, 
therefore, a full understanding of the cultural barriers to predictive testing was not 
achieved.  
 
Besides these limitations, this study has a number of strengths. Relatives were sampled 
from centres in 3 different European countries and saturation of the main themes was 
achieved by combining interview data from all centres; furthermore, no differences in the 
views expressed by relatives sampled from different European countries were detected.  
Gathering data from multiple countries means that interventions developed based on these 
data are likely to be relevant in multiple contexts. A further strength of this study was the 
support given by an international panel of patient research partners who advised 
researchers and acted as co-researchers.  
 
Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and 
consequence of future disease; however, our data show that relatives have concerns about 
predictive testing and risk information that would result from it (the key messages of this 
study are summarised in tabled 7). The future development of strategies to quantify and 
communicate risk needs to take these views into account and incorporate approaches to 
mitigate concerns and minimize any negative psychological impact of risk information. 
 
Data Sharing Statement 
Unpublished data is available in the form of unanalysed interview transcripts sorted in an 
NVIVO file from the corresponding author. Data can be obtained by emailing the 
corresponding author. 
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Table 1: Sample interview schedule for those at risk of developing RA  
 
• Tell me what you know about RA?  
PROMPTS: What do you think the causes of RA could be? What do you think the risks factors 
for RA are? Tell me about how serious you think RA is? How would you know you had RA e.g 
what symptoms would you expect? What would be the impact of RA on your life? Do you 
think you would be able to control RA yourself? Do you think there are treatments available 
that would effectively treat RA? 
• Do you ever worry about the possibility of developing RA in the future?  
• What would you think if you were told that you could have a test that would tell you 
how likely you were to develop RA?  
PROMPTS: What sort of information should this test give you? When do you think would be 
the right time to get this information? How would you feel about the idea of having a test 
that would tell you your chance of   developing RA in the future? In what ways do you think 
it would be helpful for you to know your chances of developing RA?  
• What would your concerns be if you knew what your risk of developing RA was? 
• What kind of tests do you think people might be able to do to work out whether or 
not you might develop RA (test that are available now and tests that might become 
available in the future)?  
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Table 2: Details of first degree relatives of RA patients who participated in the interviews  
 
Participant 
no.  
Gender  Age Ethnicity  Relation 
to RA 
patient 
Experience 
of testing 
Self-reported 
musculoskeletal 
symptoms  
Interview 
country 
Participant 
1  
Female  36  White 
British 
Daughter
  
None  None  UK 
Participant 
2 
Female  42 White 
British 
Daughter  
  
None  Previous septic 
arthritis  
UK 
Participant 
3  
Male 35 White 
British 
Son  None  None UK 
Participant 
4 
Male  67 White 
British 
Brother  None  None UK 
Participant 
5 
Male 31 White 
British 
Son  Reports 
having had 
a “genetic 
test” for RA 
(performed 
by family 
physician).  
None UK 
Participant 
6  
Female  23 White 
British 
Daughter  
  
None  None UK 
Participant 
7 
Female  30 White 
British 
Daughter  
  
None  Ankle pain and 
intermittent 
ankle swelling 
attributed by 
patient to a 
previous “ankle 
dislocation” 
UK 
Participant 
8  
Female  39 White 
British 
Daughter  Rheumatoid 
factor 
Elbow pain  UK 
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previously 
measured 
Participant 
9 
Female  54 White 
British 
Sister  
  
None Finger pain  UK 
Participant 
10 
 
Female  35 White 
British 
Daughter
  
None  “Inflamed 
knee”  during 
pregnancy  
UK 
Participant 
11 
 
 
 
Female  44 White 
British 
Sister 
AND 
Daughter  
  
None  Back pain UK 
Participant 
12 
 
 
 Female  44 White 
British 
Sister  
  
None  Finger pain UK 
Participant 
13 
 
 Female  41 White 
British 
Sister 
AND 
Daughter  
  
Rheumatoid 
factor 
previously 
measured 
by family 
physician 
Finger pain, 
stiffness and 
swelling 
UK 
Participant 
14 
 Female  60 White  Daughter  Has had 
“blood 
tests” 
(participant 
unsure 
which)  
 Has a diagnosis 
of osteoarthritis  
UK 
Participant 
15 
 
 Female  
  
 29 White 
British 
Daughter  None None  UK 
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Participant 
16   
 
 
Female           40 White 
British 
Daughter  None None UK 
Participant 
17  
 
Female  41 Asian 
(UK 
born)  
Daughter  None None  UK 
Participant 
18  
 
Female  28 White 
British  
Daughter  None None  UK 
Participant 
19  
 
Male 42 Chinese  Son  None None  UK 
Participant 
20  
 
Female 25 White 
British 
Daughter  None None  UK 
Participant 
21  
 
Female 41 White 
British 
Daughter  None Had previous 
joint swelling in 
wrists and 
hands 
UK 
Participant 
22  
 
Female  32 White 
British 
Sister  None None  UK 
Participant 
23  
 
Female 44 White 
British 
Daughter  None None  UK 
Participant 
24  
 
Male  47 White 
British  
Son  None None  UK 
Participant 
25  
Female  29 White 
German 
Daughter  None None  Germany  
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Participant 
26  
 
Female 37 White 
German 
Daughter  None None  Germany 
Participant 
27  
 
Female 51 White 
German 
Daughter  None None Germany  
Participant 
28 
Female  21 White 
Austrian  
Daughter  None None Austria 
Participant 
29  
Male  33 White 
Austrian 
Son  None None Austria 
Participant 
30  
Female  65 White 
Austrian 
Sister  None None Austria 
Participant 
31  
Female  36 White 
Austrian 
Sister  Reports 
having had 
a blood test 
None Austria 
Participant 
32  
 
Male  37 White 
Austrian 
Son  None None Austria 
Participant 
33  
 
Male  37 White 
Austrian 
Son  None None Austria 
Participant 
34  
 
Female  33 White 
Austrian 
Daughter  None None Austria 
        
Page 27 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
24 
 
Table 3 Quotations related to an understanding of family history and genetic factors as 
risk factors for rheumatoid arthritis  
 
Code  Quotation 
Q1  “I see that my mother has it and I’m just worried that it might be passed on to me or 
my sister or other members of my family.” (Participant 19) 
Q2 “In my opinion it’s environmental factors or genetics.” (Participant 28) 
Q3 “So I know it’s blood-related... I think if it was your cousin or your aunt there’d be a 
slim chance….. being direct blood-related, I would class myself as, or think of myself 
that I am at a higher risk than most.”( Participant 6)  
Q4 “I seem to follow my mum in absolutely everything, like my brother and sister they’re 
quite like my dad, they never get ill, they never catch a cold.  Whereas if there’s a cold 
going around I will get it and the same with my mum… So I was a bit like ‘oh, maybe 
I’ll get it’.” (Participant 18)  
Q5 “I know that there’s a genetic tendency. That it runs in families. I’m female, so I’m 
more at risk because I’m female… I know first degree relative increases your risk, so 
yeah, it does worry me.” (Participant 10) 
Q6 “Genetics really worry me because I don’t know anything about them and I think 
when people think of genetics they think of like I don’t know it’s quite like a 
complicated thing that we’re never going to understand because there’s no simple 
way of putting it….. But like your average Joe Bloggs [average person] isn’t going to 
know extensive information about your genes.” (Participant 20) 
Q7 “For me personally it’s kind of hard facts and figures; I’m more comfortable knowing 
in terms of percentages.  I know my dad has got rheumatoid arthritis, and if you’ve 
got a hard fact and figure to say that the chances of a close relative, son or daughter, 
developing rheumatoid arthritis at some point in their life then that information 
would be useful to me.” (Participant 5) 
Q8 “It [life] wouldn’t be predictable anymore; I wouldn’t know how things would be 
from one day to the next, or in an hour’s time, when I woke up the next morning, 
wondering what the day would bring. I think it’s pretty serious, it restricts your 
everyday life. And it differs – my father has pain and sometimes it’s there, 
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sometimes it’s not; it’s unpredictable.”  (Participant 25) 
Q9 “I do worry about it, yeah, because I don't want to end up developing anything like 
that.  I like to keep busy and I don't want to be restricted.  It is a big worry, yeah.  I 
don't want to go through what my mum's going through at the moment, because 
she's been through a lot.” (Participant 13) 
Q10 “I’ve got pain down my left leg [okay], but I just don’t know whether it’s sciatica, or 
whether it could be something linked to arthritis, but I’m too frightened to go and 
have a scan. So I probably do need it to find that. I’m just putting it off.” (Participant 
15) 
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Table 4 Quotation related to personal considerations of rheumatoid arthritis risk and 
communication about risk within families  
Code  Quotation 
Q11 “That’s exactly what he doesn’t talk to me about, he’s the kind of person who 
leaves others out of it, deals with it by himself.” (Participant 30) 
Q12 “I am worried about that….I was quite surprised when mum said that she'd had 
this letter explaining about the research that you're doing.” (Participant 23)   
Q13 “He doesn’t tend to talk about it.  He didn’t want to ask me to do this phone call, 
but forced himself to one day…This is probably the first time he’s actually asked 
me to do anything and he was clearly uncomfortable.” (Participant 24)     
Q14 “I never had that information of what happens, how you’re made at higher risk, 
I’ve never had that in like black and white ….which makes me think she doesn’t 
know or maybe she’s just trying to protect me like a mother does. Because I think 
she was quite worried about me taking part….she’s quite worried about what I’d 
find out. (Participant 5) 
Q15 “My mum, sort of, mentioned this to him [brother], and he was just, like, ignored 
the fact that she’d said anything to me. And then she came to me and said, ‘I 
thought I’d ask your brother first but he won’t,’ and I said, ‘I don’t mind,’ but he’s 
probably different to me, just blissful ignorance, whereas I’m probably a little bit 
different.” (Participant 2) 
Q16 “Up until now I have never thought about it, what that would be like, whether it 
might happen” (Participant 28) 
Q17  “I guess before we spoke I couldn’t understand what it was exactly that was 
making her finger sore or swollen or anything like that.  I would just be like, drink 
more milk.” (Participant 20) 
Q18 “You only worry too much and rack your brain, because then I have to consider 
that my children could get it too and then you would worry too much. It’s more 
comfortable to avoid it.” (Participant 32,) 
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Table 5 Quotations related to perceptions surrounding the use of predictive tests: positive 
perspectives 
 
Code Quotation  
Q19 “I’m open to everything, well, I don’t know why I shouldn’t have that done, I couldn’t 
think of a reason off the top of my head not to do it.” (Participant 31)  
Q20 “If I was offered a test, I’d be very happy to have one.  I don’t need to think about 
that. Well, it might be if it might help me combat a disease later, or at least know 
how to treat it. Well, if I’m at risk I think it would be helpful to know.” (Participant 3) 
Q21 “I would do that straight away, because I want to know as soon as possible, because 
I think the more you know the earlier, the more you can do about it.” (Participant 
31)  
Q22 “I think that with kind of information, I’d be more keen to, sort of, sort out what I 
needed to do to try and prevent that becoming a problem. If I could take some sort 
of medication to…head it off before it became a big problem.” (Participant 2) 
Q23 “I think that would be a good thing.  I think I’d like to know because then I may be 
able to prepare a bit more, like mentally as well.” (Participant 20) 
Q24 “Yes, it would.  I think I would have the test just to see what the long-term forecast 
is, because my job’s fairly labour intensive.  I’d be willing to know what the future 
holds, just from the point of view of my job circumstances at work.” (Participant 19) 
Q25  “Actually I did get tested, but it was a long time ago.” (Participant 27) 
Q26 “I’m not averse to having them, especially, if it helps with research and stuff like 
that.” (Participant 2) 
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Table 6 Quotations related to perceptions surrounding the use of predictive tests: 
negative perspectives 
 
Code  Quotation  
Q27 “Exactly, if it is only a vague presumption where they say, yes, you could perhaps 
out of two to five people or something, you could get it and the others wouldn’t, 
well that is very vague. (Participant 32) 
Q28 “That depends on the test, how specified it is and how sensitive it is, otherwise I 
would not have the test done.” (Participant 29) 
Q29 “Because if told me – it’s only how likely, it’s not a, ‘You will develop it,’ and it 
doesn’t tell you when you will develop it. So I think if somebody said to me, ‘There’s 
this test out there and it’ll tell you whether you might develop it,’ I wouldn’t want 
it, because you could just live your life in fear and never actually develop it. So 
unless it was 100% guaranteed, and somebody could say, ‘You will develop it 
within this time frame,’ I don’t wanna [want to] spend the next 30 years worrying 
about something, when I could be enjoying those 30 years. So, no, I’d probably – it 
depends on the exact details of the test. (Participant 10) 
Q30 “Or, equally, I guess, false positive. If you’ve got one really bad, sort of, joint that 
you’ve tested, it could, kind of, put a bit of a negative spin on it.” (Participant 1) 
Q31 “It would be nice to know when … at what point in time you were going to get ill, 
and how severe it was going to be … but I don’t know whether a test can find that 
out. (Participant 25) 
Q32 “But I wouldn’t want to worry my mum by saying, can you get me a leaflet on 
testing. I wouldn’t want my mum to worry that I was going for this test….to know 
that if in five years time I’ll get it, I don’t want her to know that because I think that 
would worry her more than anything.” ( Participant 6) 
Q33 “On the one hand you know that you might develop the disease and it is of course 
stressful, because then you know, one day, when I’m about 30 – 40 years old, it will 
start  and then my body will become weaker and I will get this disease, then it 
could create a lot of stress to have these negative thoughts. I don’t know what the 
psychological effect would be on the body, whether it really might break out 
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sooner. If you don’t know, so, if you say, I don’t know and you live each day as it 
comes, meaning that it might break out at a later date.” (Participant 32)  
Q34 “From personal experience, I think it would be something that when I got a bit 
older and certain things started going wrong with me or I started getting more 
illnesses I’d think I’d need to start looking to what all these problems are.  At this 
particular moment in time, when there’s generally nothing wrong with me, I just 
think that I don’t really need to delve too much into that sort of 
information.”(Participant 4) 
Q35 “Yeah I kind of wouldn’t want this test to tell me that I had a 50/50 chance of getting 
it in the next five years because that would change my entire perception on what I 
wanted. And I guess if someone gave me that bit of information I’d have to seriously 
think, well maybe I can’t have that, maybe I’ve got to like push everything forward 
like get married and have kids before I start to take medication which I guess that’s a 
lot of information I don’t know about in that if I had to start taking that medication 
would that affect me having kids. It’s like knowing when you’re going to die that 
doesn’t sit right with me either.” (Participant 15)  
Q36 “I think, if, for argument’s sake, I’d gone for the test tomorrow, and the results came 
back and they said, ‘Yeah, you’re at high risk,’ and in two years’ time, the symptoms 
kicked in, you’re then thinking, ‘Right, okay.’ We’d probably want a second child and 
we’d want a third, ‘Let’s do it now,’ sort of, thing, but otherwise, I think, you know, 
just life would carry on” (Participant 6,) 
Q37 
“The GP [family physician] literally just sat me down, blurted some technical words 
out, medical terminology to me that went straight over my head and, again, didn’t 
sink. I think, just keep simple, instead of baffling people with medical science, really, 
of your technical words that you use, compared to what, sort of, the general public 
are going to understand.” (Participant 6) 
Q38 “I’d be happy, I think, if, before the test, someone would explain the kind of outcome 
to expect. And then when I got the test results back, it would be okay by post, as 
long as there was, kind of, accompanying information. I suppose at that point you’d 
probably end up going to see someone anyway to talk through what tablets or 
whatever you could take.” (Participant 1)  
Page 33 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
30 
 
Q39 “I suppose it would be sensible to go and talk to somebody about it. (Participant 3) 
Q40 “I think it’s a good idea to talk to somebody and find out more information.  I think 
seeing somebody on a regular basis, like every year or something, might be good if 
you knew that you were going to get it.  Obviously, you’re going to have more and 
more questions, aren’t you?  Yeah, for an update and just to see how things are 
going.  Obviously, as time goes on, you’re going to have more questions and so I 
think it would be good to speak to somebody.” (Participant 20) 
 
 
Table 7: Key messages 
1. Identifying those at risk of RA, and quantifying their risk, may help guide targeted 
interventions to reduce future disease burden. This qualitative study found that first-
degree relatives of people with RA, who are themselves at an enhanced risk of RA, had a 
number of concerns in relation to predictive testing.  
2. Some relatives would be unwilling to undergo predictive testing and were worried about 
the psychological impact of risk information. Others were more receptive and recognized 
that such information could facilitate the development and implementation of preventive 
strategies as well as encouraging prompt help-seeking and intervention at the onset of RA 
symptoms.  
3. Developing strategies which communicate risk information effectively while reducing the 
psychological burden associated with this information is essential. 
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Abstract 
 
Objectives: The family members of rheumatoid arthritis (RA) patients are at increased risk 
of developing RA and are potential candidates for predictive testing. This study explored the 
perceptions of first degree relatives of people with RA about being at risk of RA and 
engaging in predictive testing.   
 
Methods: Thirty-four first-degree relatives (siblings and off-spring) of patients with RA from 
the UK, Germany and Austria participated in semi-structured interviews about their 
perceptions of RA isk and the prospect of predictive testing. Interviews were audio-
recorded, transcribed verbatim and analysed using thematic analysis.  
 
Results: First-degree relatives were aware of their susceptibility to RA, but were unsure of 
the extent of their risk. When considering their future risk, some relatives were concerned 
about the potential impact that RA would have on their lives. Relatives were concerned that 
knowing their actual risk would increase their anxiety and would impact decisions about 
their future. Also, relatives were concerned about the levels of uncertainty associated with 
predictive testing. Those in favour of knowing their future risk felt that they would need 
additional support to understand the risk information and cope with the emotional impact 
of this information.  
 
Conclusions: Identifying individuals at risk of RA may allow targeted interventions to reduce 
the risk and consequence of future disease; however, relatives have concerns about 
predictive testing and risk information.  The development of strategies to quantify and 
communicate risk needs to take these views into account and incorporate approaches to 
mitigate concerns and minimize the psychological impact of risk information. 
 
Strengths and limitations  
• This study used inductive qualitative interviews to explore perceptions about risk 
and predictive testing in the first-degree relatives of people with RA.  
• This study identified positive and negative perspectives surrounding predictive 
testing, and why some people at risk may not wish to be tested.    
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• Further research is needed to quantify the numbers of people at risk holding 
negative perceptions about predictive testing, and identify the behavioural 
implications of these beliefs.  
• Communicating risk information to relatives effectively while reducing the 
psychological burden associated with this information, should be the focus of future 
interventional research. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic destructive polyarthritis. It affects approximately 1% 
of the population 
1
 and  typically manifests in the 4
th
 and 5
th
 decades of life.
2-4
  Delays in 
diagnosis and treatment of RA are common and are associated with worse outcomes.
5-8
 
Recently, an increased research effort has been directed towards the ‘at risk’ phases of RA, 
prior to the development of clinical signs of joint swelling, to identify those at risk of 
developing RA and to reduce this risk through the modification of environmental risk factors 
and pharmacological intervention.
9;9-11
 
Genetic factors contribute significantly to the risk of RA.
12
 For seropositive RA at least half of 
the risk is conferred by genetic risk factors 
13
 with recent large genetic studies having 
identified over 100 susceptibility loci.
14;15
 Population based epidemiological studies have 
shown that having a family history of RA increases the risk of RA by approximately 3-5 
times,
16-18
 with the risk being higher in first degree relatives than second degree relatives.
17
 
Furthermore, a range of environmental and life-style risk factors including occupational 
exposure to pollutants,
19
 body mass index,
20
  periodontitis,
21
  reproductive factors,
22
 
smoking,
23
 and dietary factors
24-26
 contribute to the increased risk of developing RA. Some 
of these environmental risk factors may interact mechanistically with genetic risk factors to 
increase the risk of RA,
27
 and others may have familial associations thus contributing to the 
familial aggregation of RA.
28;29
  
 
Individuals with genetic and environmental risk factors for RA may progress through a phase 
associated with the development of systemic autoimmunity (e.g. the development of 
autoantibodies such as rheumatoid factor,
30;31
 anti–citrullinated protein / peptide 
antibodies and anti-carbamylated protein antibodies
32
) before the clinical symptoms and 
signs of RA manifest.
9
 It remains unclear whether there are changes detectable within the 
synovium during the phase of autoantibody positivity prior to the development of joint 
swelling.
33;34
  
 
Together these data suggest that information related to genotype, environmental exposures 
and measures of autoimmunity and inflammation may be used to predict RA development 
in individuals who have not yet developed clinical disease. A potential target population for 
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such testing, with a view to risk stratification and intervention to modulate risk, are the first-
degree relatives of individuals with RA. Indeed a number of ongoing prospective studies are 
recruiting the first-degree relatives of patients with RA to study disease mechanisms driving 
the switch to RA,
35
 to develop predictive algorithms for RA, and to test interventions to 
reduce RA risk.
36
 Whilst considerable research effort is thus focussed on the first-degree 
relatives of RA patients, and a qualitative study has gathered data relating to their views of 
preventive strategies,
37
 little is known about how such individuals view issues related to 
their susceptibility to and risk of developing RA, and  how willing they would be to be 
assessed and tested to have this risk quantified. The present qualitative study addresses 
these issues.  
 
Methods 
Ethical approval was obtained in the UK from the HumberBridge National Research Ethics 
Committee, in Austria from the Ethics Committee of the Medical University of Vienna and in 
Germany from the Ethics committee of the University of Erlangen-Nuremberg.  
  
 
Procedure  
 
Eligible participants were the first-degree relatives (offspring and siblings) of people with 
RA. Participants were required to be at least 18 years of age and without a diagnosis of 
inflammatory joint disease.   
 
Patients with RA were approached during routine secondary care clinics in Birmingham 
(United Kingdom), Erlangen (Germany) and Vienna (Austria) and were given a letter to pass 
on to a first-degree relative of their choosing inviting them to participate in an interview 
about risk and predictive testing for RA. Participants were recruited between October 2014 
and October 2015. It was explained to patients that it was entirely at their discretion 
whether to pass on the invitation letter. All research participants (i.e. the participating first-
degree relatives) gave written informed consent prior to interview. 
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The semi-structured interviews were guided by an interview schedule which was informed 
by a review of the qualitative literature exploring perceptions of risk and testing in those at 
risk of developing a chronic disease.
38;39
 The interviews aimed to assess personal 
perceptions of risk, therefore, one-to-one interviews were conducted. In addition, an 
international multi-disciplinary team of healthcare professionals, patient research partners 
and researchers working on the EuroTEAM project (www.team-arthritis.eu) reviewed and 
redrafted the interview schedule (see table 1 for sample questions from the final interview 
schedule).  
 
One-to-one Interviews were conducted at local hospitals or by telephone (for those 
participants who had difficulty in attending the hospital for a face-to-face interview). 
Interviews lasted between 30 and 90 minutes and were digitally audio-recorded. In the UK, 
participants who wanted further information about arthritis were advised to contact 
Arthritis Research UK, the National Rheumatoid Arthritis Society or the local hospital’s 
Patient Advice and Liaison Service. Participants in Austria and Germany were advised to 
contact the local rheumatology outpatient clinic.  
 
The interviews were transcribed verbatim. Interviews conducted in German were translated 
into English following transcription. Transcripts were anonymised and analysed centrally in 
Birmingham, UK, by RJS.  
 
Analysis procedure 
Data collection and analysis were carried out in parallel to assess when thematic saturation 
of major developing themes had been achieved. The data were analysed using a thematic 
approach
40
 facilitated by NVivo (a qualitative software programme).
41
 Transcripts were 
subjected to line-by-line coding by RJS. Patient research partners blind coded three 
transcripts to develop reliable and inclusive themes informed by multiple perspectives. 
Discussion of the coding framework took place between researchers and patient research 
partners. Coding categories that lacked concordance were discussed and absorbed into the 
coding framework. The initial codes were then grouped into the most noteworthy and 
frequently occurring categories. The core themes extracted and presented here focus on 
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perceptions of first-degree relatives about their personal risk of RA and their views on being 
tested.   
 
Results  
 
Thirty-four first-degree relatives of patients with RA participated, 24 from the UK, 3 from 
Germany and 7 from Austria.  Six participants were siblings of an RA patient, 26 were the 
adult offspring an RA patient and 2 participants had both a sibling and a parent with RA. 
Participants were aged between 23 and 67 years (mean 39 years) and 26 (76%) were female 
(see table 2 for participant characteristics).  Quotations are presented in tables 3, 4, 5 and 6 
and are referred to in the text using “Q” followed by the quotation code.  
 
Understanding of family history and genetic factors as risk factors for RA  
The first-degree relatives of people with RA understood that there was a hereditary 
component to RA (Q1), and often used the word “genetic” to describe the cause of their 
increased risk (Q2).  First-degree relatives (from here on referred to as “relatives”) 
recognised that they were more susceptible to developing RA than second-degree relatives 
(Q3). Interestingly, some felt that they were more susceptible to developing RA than other 
first-degree relatives because they appeared to follow other patterns of illness displayed by 
their relative with RA (Q4).  Additional biological factors, such as being female and some 
environmental factors were also described as playing a role in the development of RA 
(Q2&5).   
 
When considering their perceived personal susceptibility, relatives reported that there were 
aspects of familial risk, particularly genetic susceptibility, which they found difficult to 
understand. One relative felt that effectively communicating an understanding of genetic 
risk to the public was extremely challenging (Q6). Others felt that they needed more 
information about their level of risk as a relative and the specific role that genes associated 
with RA played in this risk (Q7).  
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When considering their susceptibility to RA, relatives voiced their concerns about the future, 
and how being at risk of developing RA was a worry for them. Those who had considered 
their personal susceptibility to RA, described being fearful of what they may uncover if they 
were to have their risk quantified. For some, the prospect of living with RA would entail 
great amounts of uncertainty (Q8). For many, having witnessed the impact of RA on their 
sibling / parent, heightened the worry they felt in relation to the possibility of developing RA 
themselves in the future (Q9). Interestingly, a small number of relatives had experienced 
joint related symptoms but had not yet sought medical advice, being fearful of the potential 
outcome (Q10).  
 
Personal considerations of RA risk and communication about risk within families  
Relatives discussed knowing little about RA or its risk factors, feeling that they had been 
“shielded” or “protected” from this knowledge by their sibling / parent (Q11). Also, relatives 
described how they rarely discussed RA within their family unit, and in some cases the 
invitation to participate in this study was the first time that the opportunity to discuss RA, 
and its risk had emerged (Q12). For one relative, receiving the invitation to take part in this 
study facilitated the first conversation he had had with his father about RA (Q13). Another 
described how his mother had had some concerns about him taking part in this study, 
because of the worry which discussing issues surrounding risk and predictive testing may 
cause (Q14). One relative described how her brother had been asked to take part in this 
study, but ignored the request; her mother had then approached her and encouraged her to 
participate (Q15). This relative suggested that it was her attitude towards health which set 
her apart from her brother.   
Most relatives had not fully considered issues related to their personal susceptibility to RA 
prior to being approached to take part in this study (Q16).  Some relatives indicated that 
taking part in this study had been a positive experience for them and had provided them 
with much needed knowledge, a chance for reflection on their risk and a greater 
understanding of RA and how it affected their sibling / parent (Q17). However, others 
described how they would prefer to avoid considering their personal risk of RA to avoid 
experiencing worry or anxiety about the future (Q18). 
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Perceptions surrounding the use of predictive tests: positive perspectives 
Most relatives were in favour of the basic principle behind predictive testing - identifying 
those at risk and quantifying the level of risk (Q19). It was also felt that the information 
gained from predictive testing could be acted upon to reduce the future risk of developing 
RA (Q20). In particular, relatives recognised the importance of early intervention, and were 
aware that testing could put them “on alert” for the early symptoms of RA (Q21), or 
suggested that they might be able to take preventive treatment (Q22). Many relatives felt 
that it was important to know that they were at risk, and that information related to their 
actual risk would be of value to them, allowing them to “mentally” prepare for the future 
(Q23). Others could see the benefit of preparing for the functional limitations that may be 
associated with RA (Q24).  A few had already undertaken predictive testing to explore their 
personal risk of developing RA (Q25). Some were willing to be tested for altruistic reasons 
such as taking part in research (Q26).   
 
Perceptions surrounding the use of predictive tests: negative perspectives 
The ability of predictive tests to quantify risk was widely discussed (Q27), with one 
participant questioning the specificity and sensitivity of the test (Q28). Relatives expressed a 
desire for tests that would, with a very high likelihood, be able to confirm or exclude the fact 
that they would develop RA (Q29). However, many relatives suspected that test results 
would give them an intermediate risk of developing RA and others highlighted concerns 
about “false positive” results (Q30). Some believed that predictive testing would not be able 
to give them answers to questions they thought were important for example how severe 
would their RA be   were they to develop it,  and when it would be most likely to begin 
(Q31). 
Relatives were worried about the impact of testing on their family members and in 
particular on their sibling / parent with RA (Q32). Participants felt that by seeking 
information about risk and pursuing testing that they would cause their relative with RA to 
experience stress, worry or feelings of guilt. Participants were further worried about the 
stress that predictive test results may cause them. One even suggested that such stress 
could cause the disease to develop earlier than it otherwise would (Q33).  
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Relatives felt that being given risk information when they were young would be a particular 
burden (Q34). Instead, they felt that testing should be left until later in life, when the 
chance of developing a condition like RA was higher. Risk information was considered to 
have significant implications for future life choices and could make them “rush” though life 
(Q35). One relative suggested such information could bring forward major life decisions, such 
as having children (Q36).   
 
Some relatives reflected upon previous negative personal experiences of having received 
poorly communicated test related information (Q37). For some, the approach to the 
delivery of risk information represented an important feature of a predictive test, and may 
determine whether the test would be acceptable to them. Relatives discussed how they 
would want to be told prior to the test what format the result would take. Some suggested 
that they would like to receive the results by letter, and then be given the opportunity to 
discuss the results with a healthcare professional (Q38). Other relatives emphasized the 
importance of talking to someone about the test result, especially to manage the 
psychological distress that may be associated with receiving a “positive” test result (Q39).  
Many relatives felt that there was a need for ongoing support from a healthcare 
professional following testing (Q40).  
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Discussion 
This study explored the degree to which first-degree relatives of people with RA felt that 
they were susceptible to developing RA and their perceptions of predictive testing. Most 
relatives were aware that there was a genetic contribution to the risk of RA, and that they 
may be susceptible to developing RA; however they were unsure of the extent of the 
additional risk. Relatives highlighted the need for additional information about familial risk 
and described the need for better communication strategies in relation to imparting this 
information.  
 
Generally, first-degree relatives felt that there was a need for more information and support 
specifically designed for the family members of people with RA. The current lack of support 
and information was suggested to have a number of effects, including family members not 
feeling able to communicate and support the person affected with RA and not feeling able 
to understand concepts surrounding the nature of RA and the risks associated with RA. 
Studies of information sharing amongst family members at risk of cancer have found that 
patients with the disease do not always communicate risk information in a timely or 
thorough fashion.
42
 Forrest et al found that relatives from smaller families, and female 
relatives were more likely to make contact with genetic services.
43
 Research has shown that 
genetic counselling can facilitate interfamily communication, and can help to minimize 
distress and increase the number of family members making c ntract with health services to 
be tested.
44;45
 
 
An incidental finding of this research was that being invited to take part in research about 
risk was the first time that some relatives had fully considered their personal susceptibility 
to RA. In some cases this exposure was viewed positively but in other cases it caused worry 
and concern. It is difficult to draw conclusions about the specific impact taking part in this 
study had on relatives’ well-being but we note that relatives did indicate that support 
mechanisms would be helpful to enable them to understand and cope with risk related 
information, especially if predictive testing were to be offered. We would suggest that 
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researchers accessing participants in “at risk” populations pay particular attention to the 
impact that an invitation to participate and participation itself may have, and offer 
additional support to mitigate against anxiety caused. While personal susceptibility may not 
have been considered, perceptions of RA severity may predict personal willingness to 
engage in predictive testing. It is possible that first degree relatives of people with more 
severe forms of RA or poorly controlled disease maybe more motivated to engage in 
predictive testing. This would be in line with the predictions of the health belief model.
46
 A 
quantitative investigation to assess the effect of factors such as disease severity in people 
with RA, on their family members’ perceptions of risk and orientation towards predictive 
testing is needed to test this hypothesis.  
 
In addition, it became apparent during the course of this study that some relatives were 
symptomatic but had not yet sought medical help. Detailed information on the health status 
of the participating relatives was not gathered within this study but those who were 
symptomatic were advised to speak to their family physician, and were given details of 
resources for obtaining additional information. However, the symptomatic nature of some 
relatives raises important issues surrounding informing relatives about risk, and the 
importance of seeking help quickly should symptoms emerge. While some relatives were 
aware that their symptoms may be indicative of the early stages of RA, and were worried 
about what information would be revealed to them if they sought help, few were aware of 
the importance of early intervention. Were information about the benefits of early 
intervention in preventing joint destruction made available to them, it is possible that their 
attitude to help seeking may have been different. 
 
This study has a number of limitations. Firstly, our access to first-degree relatives was via 
patients with RA. Some relatives described how they were chosen in preference to other 
relatives, who would either worry too much or not be receptive to discussing issues related 
to risk. The findings presented here may thus not fully reflect the range of views related to 
risk and testing held by first-degree relatives. This potential limitation highlights the need to 
fully understand the barriers that patients with RA face when discussing issues of risk with 
family members. A second limitation of this research was that the majority of participants 
were female. A criticism of many qualitative studies in the field of RA is that the male 
Page 47 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
14 
 
perspective is underrepresented.
8
 While the female: male ratio of RA is typically 2:1 it is 
essential that studies attempt to include the views of more male participants. Therefore, we 
acknowledge that themes related to gender and male perspectives of risk and predictive 
testing did not reach saturation and are not represented in our data. A final limitation is that 
only a small number of individuals from ethnic-minority communities were interviewed, 
therefore, a full understanding of the cultural barriers to predictive testing was not 
achieved.  
 
Besides these limitations, this study has a number of strengths. Relatives were sampled 
from centres in 3 different European countries and saturation of the main themes was 
achieved by combining interview data from all centres; furthermore, no differences in the 
views expressed by relatives sampled from different European countries were detected.  
Gathering data from multiple countries means that interventions developed based on these 
data are likely to be relevant in multiple contexts. A further strength of this study was the 
support given by an international panel of patient research partners who advised 
researchers and acted as co-researchers.  
 
Identifying individuals at risk of RA may allow targeted interventions to reduce the risk and 
consequence of future disease; however, our data show that relatives have concerns about 
predictive testing and risk information that would result from it (the key messages of this 
study are summarised in tabled 7). The future development of strategies to quantify and 
communicate risk needs to take these views into account and incorporate approaches to 
mitigate concerns and minimize any negative psychological impact of risk information. 
 
Data Sharing Statement 
Unpublished data is available in the form of unanalysed interview transcripts sorted in an 
NVIVO file from the corresponding author. Data can be obtained by emailing the 
corresponding author. 
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Table 1: Sample interview schedule for those at risk of developing RA  
 
• Tell me what you know about RA?  
PROMPTS: What do you think the causes of RA could be? What do you think the risks factors 
for RA are? Tell me about how serious you think RA is? How would you know you had RA e.g 
what symptoms would you expect? What would be the impact of RA on your life? Do you 
think you would be able to control RA yourself? Do you think there are treatments available 
that would effectively treat RA? 
• Do you ever worry about the possibility of developing RA in the future?  
• What would you think if you were told that you could have a test that would tell you 
how likely you were to develop RA?  
PROMPTS: What sort of information should this test give you? When do you think would be 
the right time to get this information? How would you feel about the idea of having a test 
that would tell you your chance of   developing RA in the future? In what ways do you think 
it would be helpful for you to know your chances of developing RA?  
• What would your concerns be if you knew what your risk of developing RA was? 
• What kind of tests do you think people might be able to do to work out whether or 
not you might develop RA (test that are available now and tests that might become 
available in the future)?  
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Table 2: Details of first degree relatives of RA patients who participated in the interviews  
 
Participant 
no.  
Gender  Age Ethnicity  Relation 
to RA 
patient 
Experience 
of testing 
Self-reported 
musculoskeletal 
symptoms  
Interview 
country 
Participant 
1  
Female  36  White 
British 
Daughter
  
None  None  UK 
Participant 
2 
Female  42 White 
British 
Daughter  
  
None  Previous septic 
arthritis  
UK 
Participant 
3  
Male 35 White 
British 
Son  None  None UK 
Participant 
4 
Male  67 White 
British 
Brother  None  None UK 
Participant 
5 
Male 31 White 
British 
Son  Reports 
having had 
a “genetic 
test” for RA 
(performed 
by family 
physician).  
None UK 
Participant 
6  
Female  23 White 
British 
Daughter  
  
None  None UK 
Participant 
7 
Female  30 White 
British 
Daughter  
  
None  Ankle pain and 
intermittent 
ankle swelling 
attributed by 
patient to a 
previous “ankle 
dislocation” 
UK 
Participant 
8  
Female  39 White 
British 
Daughter  Rheumatoid 
factor 
Elbow pain  UK 
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previously 
measured 
Participant 
9 
Female  54 White 
British 
Sister  
  
None Finger pain  UK 
Participant 
10 
 
Female  35 White 
British 
Daughter
  
None  “Inflamed 
knee”  during 
pregnancy  
UK 
Participant 
11 
 
 
 
Female  44 White 
British 
Sister 
AND 
Daughter  
  
None  Back pain UK 
Participant 
12 
 
 
 Female  44 White 
British 
Sister  
  
None  Finger pain UK 
Participant 
13 
 
 Female  41 White 
British 
Sister 
AND 
Daughter  
  
Rheumatoid 
factor 
previously 
measured 
by family 
physician 
Finger pain, 
stiffness and 
swelling 
UK 
Participant 
14 
 Female  60 White  Daughter  Has had 
“blood 
tests” 
(participant 
unsure 
which)  
 Has a diagnosis 
of osteoarthritis  
UK 
Participant 
15 
 
 Female  
  
 29 White 
British 
Daughter  None None  UK 
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Participant 
16   
 
 
Female           40 White 
British 
Daughter  None None UK 
Participant 
17  
 
Female  41 Asian 
(UK 
born)  
Daughter  None None  UK 
Participant 
18  
 
Female  28 White 
British  
Daughter  None None  UK 
Participant 
19  
 
Male 42 Chinese  Son  None None  UK 
Participant 
20  
 
Female 25 White 
British 
Daughter  None None  UK 
Participant 
21  
 
Female 41 White 
British 
Daughter  None Had previous 
joint swelling in 
wrists and 
hands 
UK 
Participant 
22  
 
Female  32 White 
British 
Sister  None None  UK 
Participant 
23  
 
Female 44 White 
British 
Daughter  None None  UK 
Participant 
24  
 
Male  47 White 
British  
Son  None None  UK 
Participant 
25  
Female  29 White 
German 
Daughter  None None  Germany  
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Participant 
26  
 
Female 37 White 
German 
Daughter  None None  Germany 
Participant 
27  
 
Female 51 White 
German 
Daughter  None None Germany  
Participant 
28 
Female  21 White 
Austrian  
Daughter  None None Austria 
Participant 
29  
Male  33 White 
Austrian 
Son  None None Austria 
Participant 
30  
Female  65 White 
Austrian 
Sister  None None Austria 
Participant 
31  
Female  36 White 
Austrian 
Sister  Reports 
having had 
a blood test 
None Austria 
Participant 
32  
 
Male  37 White 
Austrian 
Son  None None Austria 
Participant 
33  
 
Male  37 White 
Austrian 
Son  None None Austria 
Participant 
34  
 
Female  33 White 
Austrian 
Daughter  None None Austria 
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Table 3 Quotations related to an understanding of family history and genetic factors as 
risk factors for rheumatoid arthritis  
 
Code  Quotation 
Q1  “I see that my mother has it and I’m just worried that it might be passed on to me or 
my sister or other members of my family.” (Participant 19) 
Q2 “In my opinion it’s environmental factors or genetics.” (Participant 28) 
Q3 “So I know it’s blood-related... I think if it was your cousin or your aunt there’d be a 
slim chance….. being direct blood-related, I would class myself as, or think of myself 
that I am at a higher risk than most.”( Participant 6)  
Q4 “I seem to follow my mum in absolutely everything, like my brother and sister they’re 
quite like my dad, they never get ill, they never catch a cold.  Whereas if there’s a cold 
going around I will get it and the same with my mum… So I was a bit like ‘oh, maybe 
I’ll get it’.” (Participant 18)  
Q5 “I know that there’s a genetic tendency. That it runs in families. I’m female, so I’m 
more at risk because I’m female… I know first degree relative increases your risk, so 
yeah, it does worry me.” (Participant 10) 
Q6 “Genetics really worry me because I don’t know anything about them and I think 
when people think of genetics they think of like I don’t know it’s quite like a 
complicated thing that we’re never going to understand because there’s no simple 
way of putting it….. But like your average Joe Bloggs [average person] isn’t going to 
know extensive information about your genes.” (Participant 20) 
Q7 “For me personally it’s kind of hard facts and figures; I’m more comfortable knowing 
in terms of percentages.  I know my dad has got rheumatoid arthritis, and if you’ve 
got a hard fact and figure to say that the chances of a close relative, son or daughter, 
developing rheumatoid arthritis at some point in their life then that information 
would be useful to me.” (Participant 5) 
Q8 “It [life] wouldn’t be predictable anymore; I wouldn’t know how things would be 
from one day to the next, or in an hour’s time, when I woke up the next morning, 
wondering what the day would bring. I think it’s pretty serious, it restricts your 
everyday life. And it differs – my father has pain and sometimes it’s there, 
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sometimes it’s not; it’s unpredictable.”  (Participant 25) 
Q9 “I do worry about it, yeah, because I don't want to end up developing anything like 
that.  I like to keep busy and I don't want to be restricted.  It is a big worry, yeah.  I 
don't want to go through what my mum's going through at the moment, because 
she's been through a lot.” (Participant 13) 
Q10 “I’ve got pain down my left leg [okay], but I just don’t know whether it’s sciatica, or 
whether it could be something linked to arthritis, but I’m too frightened to go and 
have a scan. So I probably do need it to find that. I’m just putting it off.” (Participant 
15) 
 
  
Page 59 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
26 
 
Table 4 Quotation related to personal considerations of rheumatoid arthritis risk and 
communication about risk within families  
Code  Quotation 
Q11 “That’s exactly what he doesn’t talk to me about, he’s the kind of person who 
leaves others out of it, deals with it by himself.” (Participant 30) 
Q12 “I am worried about that….I was quite surprised when mum said that she'd had 
this letter explaining about the research that you're doing.” (Participant 23)   
Q13 “He doesn’t tend to talk about it.  He didn’t want to ask me to do this phone call, 
but forced himself to one day…This is probably the first time he’s actually asked 
me to do anything and he was clearly uncomfortable.” (Participant 24)     
Q14 “I never had that information of what happens, how you’re made at higher risk, 
I’ve never had that in like black and white ….which makes me think she doesn’t 
know or maybe she’s just trying to protect me like a mother does. Because I think 
she was quite worried about me taking part….she’s quite worried about what I’d 
find out. (Participant 5) 
Q15 “My mum, sort of, mentioned this to him [brother], and he was just, like, ignored 
the fact that she’d said anything to me. And then she came to me and said, ‘I 
thought I’d ask your brother first but he won’t,’ and I said, ‘I don’t mind,’ but he’s 
probably different to me, just blissful ignorance, whereas I’m probably a little bit 
different.” (Participant 2) 
Q16 “Up until now I have never thought about it, what that would be like, whether it 
might happen” (Participant 28) 
Q17  “I guess before we spoke I couldn’t understand what it was exactly that was 
making her finger sore or swollen or anything like that.  I would just be like, drink 
more milk.” (Participant 20) 
Q18 “You only worry too much and rack your brain, because then I have to consider 
that my children could get it too and then you would worry too much. It’s more 
comfortable to avoid it.” (Participant 32,) 
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Table 5 Quotations related to perceptions surrounding the use of predictive tests: positive 
perspectives 
 
Code Quotation  
Q19 “I’m open to everything, well, I don’t know why I shouldn’t have that done, I couldn’t 
think of a reason off the top of my head not to do it.” (Participant 31)  
Q20 “If I was offered a test, I’d be very happy to have one.  I don’t need to think about 
that. Well, it might be if it might help me combat a disease later, or at least know 
how to treat it. Well, if I’m at risk I think it would be helpful to know.” (Participant 3) 
Q21 “I would do that straight away, because I want to know as soon as possible, because 
I think the more you know the earlier, the more you can do about it.” (Participant 
31)  
Q22 “I think that with kind of information, I’d be more keen to, sort of, sort out what I 
needed to do to try and prevent that becoming a problem. If I could take some sort 
of medication to…head it off before it became a big problem.” (Participant 2) 
Q23 “I think that would be a good thing.  I think I’d like to know because then I may be 
able to prepare a bit more, like mentally as well.” (Participant 20) 
Q24 “Yes, it would.  I think I would have the test just to see what the long-term forecast 
is, because my job’s fairly labour intensive.  I’d be willing to know what the future 
holds, just from the point of view of my job circumstances at work.” (Participant 19) 
Q25  “Actually I did get tested, but it was a long time ago.” (Participant 27) 
Q26 “I’m not averse to having them, especially, if it helps with research and stuff like 
that.” (Participant 2) 
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Table 6 Quotations related to perceptions surrounding the use of predictive tests: 
negative perspectives 
 
Code  Quotation  
Q27 “Exactly, if it is only a vague presumption where they say, yes, you could perhaps 
out of two to five people or something, you could get it and the others wouldn’t, 
well that is very vague. (Participant 32) 
Q28 “That depends on the test, how specified it is and how sensitive it is, otherwise I 
would not have the test done.” (Participant 29) 
Q29 “Because if told me – it’s only how likely, it’s not a, ‘You will develop it,’ and it 
doesn’t tell you when you will develop it. So I think if somebody said to me, ‘There’s 
this test out there and it’ll tell you whether you might develop it,’ I wouldn’t want 
it, because you could just live your life in fear and never actually develop it. So 
unless it was 100% guaranteed, and somebody could say, ‘You will develop it 
within this time frame,’ I don’t wanna [want to] spend the next 30 years worrying 
about something, when I could be enjoying those 30 years. So, no, I’d probably – it 
depends on the exact details of the test. (Participant 10) 
Q30 “Or, equally, I guess, false positive. If you’ve got one really bad, sort of, joint that 
you’ve tested, it could, kind of, put a bit of a negative spin on it.” (Participant 1) 
Q31 “It would be nice to know when … at what point in time you were going to get ill, 
and how severe it was going to be … but I don’t know whether a test can find that 
out. (Participant 25) 
Q32 “But I wouldn’t want to worry my mum by saying, can you get me a leaflet on 
testing. I wouldn’t want my mum to worry that I was going for this test….to know 
that if in five years time I’ll get it, I don’t want her to know that because I think that 
would worry her more than anything.” ( Participant 6) 
Q33 “On the one hand you know that you might develop the disease and it is of course 
stressful, because then you know, one day, when I’m about 30 – 40 years old, it will 
start  and then my body will become weaker and I will get this disease, then it 
could create a lot of stress to have these negative thoughts. I don’t know what the 
psychological effect would be on the body, whether it really might break out 
Page 62 of 64
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
29 
 
sooner. If you don’t know, so, if you say, I don’t know and you live each day as it 
comes, meaning that it might break out at a later date.” (Participant 32)  
Q34 “From personal experience, I think it would be something that when I got a bit 
older and certain things started going wrong with me or I started getting more 
illnesses I’d think I’d need to start looking to what all these problems are.  At this 
particular moment in time, when there’s generally nothing wrong with me, I just 
think that I don’t really need to delve too much into that sort of 
information.”(Participant 4) 
Q35 “Yeah I kind of wouldn’t want this test to tell me that I had a 50/50 chance of getting 
it in the next five years because that would change my entire perception on what I 
wanted. And I guess if someone gave me that bit of information I’d have to seriously 
think, well maybe I can’t have that, maybe I’ve got to like push everything forward 
like get married and have kids before I start to take medication which I guess that’s a 
lot of information I don’t know about in that if I had to start taking that medication 
would that affect me having kids. It’s like knowing when you’re going to die that 
doesn’t sit right with me either.” (Participant 15)  
Q36 “I think, if, for argument’s sake, I’d gone for the test tomorrow, and the results came 
back and they said, ‘Yeah, you’re at high risk,’ and in two years’ time, the symptoms 
kicked in, you’re then thinking, ‘Right, okay.’ We’d probably want a second child and 
we’d want a third, ‘Let’s do it now,’ sort of, thing, but otherwise, I think, you know, 
just life would carry on” (Participant 6,) 
Q37 
“The GP [family physician] literally just sat me down, blurted some technical words 
out, medical terminology to me that went straight over my head and, again, didn’t 
sink. I think, just keep simple, instead of baffling people with medical science, really, 
of your technical words that you use, compared to what, sort of, the general public 
are going to understand.” (Participant 6) 
Q38 “I’d be happy, I think, if, before the test, someone would explain the kind of outcome 
to expect. And then when I got the test results back, it would be okay by post, as 
long as there was, kind of, accompanying information. I suppose at that point you’d 
probably end up going to see someone anyway to talk through what tablets or 
whatever you could take.” (Participant 1)  
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Q39 “I suppose it would be sensible to go and talk to somebody about it. (Participant 3) 
Q40 “I think it’s a good idea to talk to somebody and find out more information.  I think 
seeing somebody on a regular basis, like every year or something, might be good if 
you knew that you were going to get it.  Obviously, you’re going to have more and 
more questions, aren’t you?  Yeah, for an update and just to see how things are 
going.  Obviously, as time goes on, you’re going to have more questions and so I 
think it would be good to speak to somebody.” (Participant 20) 
 
 
Table 7: Key messages 
1. Identifying those at risk of RA, and quantifying their risk, may help guide targeted 
interventions to reduce future disease burden. This qualitative study found that first-
degree relatives of people with RA, who are themselves at an enhanced risk of RA, had a 
number of concerns in relation to predictive testing.  
2. Some relatives would be unwilling to undergo predictive testing and were worried about 
the psychological impact of risk information. Others were more receptive and recognized 
that such information could facilitate the development and implementation of preventive 
strategies as well as encouraging prompt help-seeking and intervention at the onset of RA 
symptoms.  
3. Developing strategies which communicate risk information effectively while reducing the 
psychological burden associated with this information is essential. 
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